WO2024154045 - USE OF GAMMA PRIME FIBRINOGEN AS A BIOMARKER IN THE ASSESSMENT FOR TREATMENT OF COVID-19 INFECTIONS AND LONG COVID-19
National phase entry is expected:
Publication Number
WO/2024/154045
Publication Date
25.07.2024
International Application No.
PCT/IB2024/050399
International Filing Date
16.01.2024
Title **
[English]
USE OF GAMMA PRIME FIBRINOGEN AS A BIOMARKER IN THE ASSESSMENT FOR TREATMENT OF COVID-19 INFECTIONS AND LONG COVID-19
[French]
UTILISATION DE FIBRINOGÈNE GAMMA PRIME EN TANT QUE BIOMARQUEUR DANS L'ÉVALUATION POUR LE TRAITEMENT D'INFECTIONS PAR LA COVID-19 ET DE LA COVID-19 LONGUE
Applicants **
GAMMA DIAGNOSTICS INC.
Inventors
FARRELL, David H.
OLYNYK, John K.
BAKER, Ross I.
KAZMIERCZAK, Steven C.
MESSER, William
KHAN, Akram
NAIR, Ajay Sasikumar
Priority Data
63/439,174
16.01.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter II
* |
| * | |
| * | |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1551 | |
| EPO | Filing, Examination | 9688 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 2480 |
Total:
14,883
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
A method is provided for treating a subject with an alternative therapeutic agent to heparin including a non-heparin anticoagulant, wherein the subject has been infected with COVID-19 or has symptoms of long COVID-19 post infection with COVID-19, the method comprising the steps of: obtaining or having obtained a sample from the subject, determining levels of GPF in the sample are above a reference range, and administering the alternative therapeutic agent to the subject if the GPF levels in the sample indicate the subject is heparin resistant, and wherein the alternative therapeutic agent preferably prevents activation of thrombin or reduces levels of active thrombin.[French]
L'invention concerne un procédé de traitement d'un sujet avec un agent thérapeutique alternatif à l'héparine comprenant un anticoagulant non héparine, le sujet ayant été infecté par la COVID-19 ou présentant des symptômes de la COVID-19 longue après infection par la COVID-19, le procédé comprenant les étapes suivantes : l'obtention d'un échantillon, ou l'échantillon ayant déjà été acquis, provenant du sujet, la détermination des niveaux de FGP dans l'échantillon étant au-dessus d'une plage de référence, et l'administration de l'agent thérapeutique alternatif au sujet si les niveaux de FGP dans l'échantillon indiquent que le sujet est résistant à l'héparine, et l'autre agent thérapeutique empêchant de préférence l'activation de la thrombine ou réduisant les niveaux de thrombine active.